Basilea lands US$6m CARB X boost for novel antibiotic
Amid chronic under-investments in new antibacterial weapons, Basilea Pharmaceutica has secured an additional US$6 million from CARB‑X to fund the first‑in‑human Phase I trial of a novel Gram‑negative antibiotic now entering early clinical development. The compound BAL2420 targets LptA, part of the lipopolysaccharide transport bridge that Gram negative bacteria rely on to build their outer membrane.
The money is non‑dilutive and follows the successful completion of investigational‑new‑drug‑enabling work and the project’s green‑light for clinical development, with the first subject already dosed in March 2026.
BAL2420 belongs to one of the very few new classes of antibiotics currently in clinical development. Preclinical data show potent and rapid bactericidal activity against Enterobacteriaceae such as Escherichia coli and Klebsiella pneumoniae, including strains resistant to beta‑lactams and colistin, a last‑resort antibiotic flagged by the CDC and WHO as falling short for many critical‑priority pathogens.
A scarcity of new antibacterials
The renewed CARB X backing builds on six years of support that have guided BAL2420 from hit to lead all the way into the first in human trial. As a global non profit accelerator, CARB X is one of the few early stage investors in antibacterials, a space where traditional venture and pharma sponsored capital remain thin on the ground and many antibiotic candidates struggle to attract sustained funding. CARB X, led by Boston University and funded by a patchwork of governments and foundations including the US BARDA, Wellcome, the Gates Foundation, the Novo Nordisk Foundation, and several EU and national sources, focuses exclusively on projects that tackle the most serious resistant bacteria on global priority lists. Its mandate is to de‑risk the costly early phases of development for antibacterial therapeutics, preventatives and diagnostics, particularly where the commercial pull lags behind the public‑health urgency.
For Basilea, the additional US$6m is a vote of confidence in its long‑running focus on severe bacterial and fungal infections, anchored by marketed hospital brands such as Cresemba for invasive fungal disease and Zevtera for bacterial infections. The Swiss firm now counts BAL2420 as one of several clinical and preclinical anti‑infective assets in its pipeline.
“BAL2420 offers a new mode of action with the potential to address significant unmet medical needs in the treatment of severe Gram‑negative bacterial infections including those caused by multidrug‑resistant bacteria,” commented Marc Engelhardt, Basilea’s CMO.
CARB-X
Image by freepik